BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
49.86
-0.10 (-0.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close49.89
Open49.88
Bid0.00 x 4000
Ask0.00 x 1100
Day's Range49.63 - 50.11
52 Week Range44.30 - 67.16
Volume11,534,574
Avg. Volume18,832,511
Market Cap81.404B
Beta (3Y Monthly)0.86
PE Ratio (TTM)16.56
EPS (TTM)3.01
Earnings DateApr 25, 2019
Forward Dividend & Yield1.64 (3.28%)
Ex-Dividend Date2019-01-03
1y Target Est56.70
Trade prices are not sourced from all markets
  • Reuters5 hours ago

    U.S. FDA approves Roche's small cell lung cancer treatment

    Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb. The U.S. Food and Drug Administration (FDA) approved Tecentriq plus chemotherapy for untreated extensive-stage small cell lung cancer (SCLC), after a study showed patients getting the drug cocktail lived a median 12.3 months, compared to 10.3 months for those getting chemotherapy alone, Genentech said in a statement.

  • Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
    Zacks9 hours ago

    Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

    Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).

  • Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
    Zacks12 hours ago

    Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

    Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

  • AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
    Business Wire2 days ago

    AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

    AUGUSTUS is the largest trial in this high-risk patient population requiring both anticoagulant and antiplatelet therapies

  • Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
    Motley Fool4 days ago

    Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?

    This mega-merger could be on the rocks following objections by high-profile investors.

  • Infinity Inks Deal With Roche for Phase II Study of IPI-549
    Zacks4 days ago

    Infinity Inks Deal With Roche for Phase II Study of IPI-549

    Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.

  • Merck's Keytruda Gets EU Approval for Difficult Lung Cancer
    Zacks4 days ago

    Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

    Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

  • Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
    Zacks4 days ago

    Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

    Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.

  • Some Bristol-Myers Squibb (NYSE:BMY) Shareholders Are Down 25%
    Simply Wall St.4 days ago

    Some Bristol-Myers Squibb (NYSE:BMY) Shareholders Are Down 25%

    The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do both better or worse than that.Read More...

  • J&J Seeks Approval for Darzalex in Expanded Patient Group
    Zacks4 days ago

    J&J Seeks Approval for Darzalex in Expanded Patient Group

    J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.

  • Reuters5 days ago

    U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

    The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. Shares of Celgene were up 1.2 percent at $88.33 in early trading. The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen's petition for an inter-partes review on the patents of the drug.

  • Reuters5 days ago

    U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid

    A U.S. administrative court on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen's petition for an inter-partes review on the patents of the drug. Drugmaker Bristol-Myers Squibb Co in January said it would buy Celgene Corporation for about $74 billion, to expand its pipeline of cancer drugs.

  • GuruFocus.com5 days ago

    5 Biotech Stocks to Keep an Eye on in 2019

    The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).

  • Barrons.com5 days ago

    Celgene’s Positive Drug Data Bolsters Bristol-Myers Deal, Analyst Says

    Robert W. Baird analyst Brian Skorney wrote that neither company is “a coveted prize, but both are better off together than apart.” Celgene stock is up on upbeat FDA actions.

  • Barrons.com6 days ago

    A Merck Cancer Treatment Has a Big Opportunity in China, Analyst Says

    Cantor’s Louise Chen says the potential for Merck’s Keytruda in China could equate to billions of dollars not yet in forecasts.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

    Bristol-Myers Squibb Co NYSE:BMYView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for BMY with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 4. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BMY had net inflows of $4.43 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. BMY credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Celgene (CELG) Submits Application for MS Drug in Europe
    Zacks7 days ago

    Celgene (CELG) Submits Application for MS Drug in Europe

    Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.

  • Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation
    Zacks7 days ago

    Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation

    Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.

  • 3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade
    Motley Fool7 days ago

    3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade

    These healthcare giants are taking the word "value" to an extreme.

  • GlobeNewswire7 days ago

    Biocartis Group NV: Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies

    PRESS RELEASE                                                            12 March 2019, 07:00 CET Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies ...

  • Reuters7 days ago

    Third Point holds Celgene stock, in bet Bristol-Myers deal will close -source

    Daniel Loeb's hedge fund Third Point LLC owns a small stake in Celgene Corp, betting that the proposed $74 billion sale of the biotechnology company to Bristol-Myers Squibb Co will be completed, a person familiar with the matter said on Monday. Third Point's previously undisclosed position illustrates how some prominent hedge funds are placing opposing bets on what would be the biggest-ever pharmaceutical acquisition. Activist hedge fund Starboard Value LP, which holds a small stake in Bristol-Myers, is urging its shareholders to vote down the Celgene deal.

  • Here's Why Seres Therapeutics Stock Soared Today
    Motley Fool8 days ago

    Here's Why Seres Therapeutics Stock Soared Today

    A new collaboration with AstraZeneca could give microbiome-based medicine a big lift.

  • Bayer Submits Application in EU for Prostate Cancer Drug
    Zacks8 days ago

    Bayer Submits Application in EU for Prostate Cancer Drug

    Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.

  • Is Bristol-Myers (BMY) a Solid Pick for Value Investors?
    Zacks8 days ago

    Is Bristol-Myers (BMY) a Solid Pick for Value Investors?

    Let's see if Bristol-Myers (BMY) stock is a good choice for value-oriented investors right now from multiple angles.

  • Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat
    Zacks11 days ago

    Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat

    Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.